What is CBD? The 'miracle' cannabis compound that doesn't

New Post Public Reply Private Reply Replies (0) Message Board

May 28, 2018 at 8:38 AM 539

What is CBD? The 'miracle' cannabis compound that doesn't get you high
Cannabis
High time: a grownup's guide to the cannabis revolution

The cannabis-derived chemical is non-psychoactive, and – while federally illegal – has been hailed as a cure for disease

Alex Halperin
@alexhalperin

Mon 28 May 2018 07.00 EDT
‘Many users believe CBD helps them relax ... and some believe regular doses help stave off Alzheimer’s and heart disease.’
‘Many users believe CBD helps them relax ... and some believe regular doses help stave off Alzheimer’s and heart disease.’ Illustration: George Wylesol

In early May, a federal court ruled that cannabidiol (CBD), a chemical produced by the cannabis plant, is federally illegal, in the same category as LSD and heroin, which the government considers to be dangerous and devoid of medical value.

The ruling was contrary to existing evidence, which suggests the chemical is safe and could have multiple important uses as medicine. Many cannabis advocates consider it a miracle medicine, capable of relieving conditions as disparate as depression, arthritis and diabetes.

The perception of its widespread medical benefits have made the chemical a rallying cry for legalization advocates.

The first thing to know about CBD is that it is not psychoactive; it doesn’t get people high. The primary psychoactive ingredient in marijuana is tetrahydrocannabinol (THC). But THC is only one of the scores of chemicals – known as cannabinoids – produced by the cannabis plant.

So far, CBD is the most promising compound from both a marketing and a medical perspective. Many users believe it helps them relax, despite it not being psychoactive, and some believe regular doses help stave off Alzheimer’s and heart disease.
Expots: medical marijuana draws parents to US for their children's treatments
Read more

While studies have shown CBD to have anti-inflammatory, anti-pain and anti-psychotic properties, it has seen only minimal testing in human clinical trials, where scientists determine what a drug does, how much patients should take, its side effects and so on.

Despite the government ruling, CBD is widely available over the counter in dispensaries in states where marijuana is legal.

CBD first came to public attention in a 2013 CNN documentary called Weed. The piece, reported by Dr Sanjay Gupta, featured a little girl in Colorado named Charlotte, who had a rare life-threatening form of epilepsy called Dravet syndrome.

At age five, Charlotte suffered 300 grand mal seizures a week, and was constantly on the brink of a medical emergency. Through online research, Charlotte’s desperate parents heard of treating Dravet with CBD. It was controversial to pursue medical marijuana for such a young patient, but when they gave Charlotte oil extracted from high-CBD cannabis, her seizures stopped almost completely. In honor of her progress, high-CBD cannabis is sometimes known as Charlotte’s Web.
CBD has been sought for its healing properties.
Facebook
Twitter
Pinterest
CBD has been sought for its healing properties. Illustration: George Wylesol

After Charlotte’s story got out, hundreds of families relocated to Colorado where they could procure CBD for their children, though not all experienced such life-changing results. Instead of moving, other families obtained CBD oil through the illegal distribution networks.
Advertisement

In late June, the US Food and Drug Administration could approve the Epidiolex, a pharmaceuticalized form of CBD for several severe pediatric seizure disorders. According to data recently published in the New England Journal of Medicine, the drug can reduce seizures by more than 40%. If Epidiolex wins approval it would be the first time the agency approves a drug derived from the marijuana plant. (The FDA has approved synthetic THC to treat chemotherapy-related nausea.)

Epidiolex was developed by the London-based GW Pharmaceuticals, which grows cannabis on tightly controlled farms in the UK. It embarked on the Epidiolex project in 2013, as anecdotes of CBD’s value as an epilepsy drug began emerging from the US.

While parents treating their children with CBD had to proceed based on trial and error, like a folk medicine, they also had to wonder whether dispensary purchased CBD was professionally manufactured and contained what the package said it did. GW brought a scientific understanding and pharmaceutical grade manufacturing to this promising compound.

Fortunately, like THC, CBD appears to be well tolerated; as far as I can tell, there are no recorded incidents of fatal CBD overdoses.

Since Weed first aired, GW’s stock has climbed 1,500%.
Should I grow my own weed at home? Here's what you need to know
Read more

GW’s first drug Sativex, which contains both CBD and THC, is available as a treatment for MS-related spasticity in Canada, Australia, and much of Europe and Latin America. The company is also studying cannabinoid-based drugs as a treatment for autism spectrum disorders, an aggressive brain tumor called glioblastoma, and schizophrenia.

Other industries, not subject to the strict regulations governing pharmaceuticals are eager to develop their own CBD products, everything from joints and vape pens to skin creams and edibles which may or may not have valid medical use.

In Los Angeles, it’s among the latest wellness fads. It can be found in cocktails, and an upscale juice shop will even add a few drops of CBD infused olive oil to a beverage for $3.50.

High time is the Guardian’s column about how cannabis legalization is changing modern life. Alex Halperin welcomes your thoughts, questions and concerns and will protect your anonymity. Get in touch:high.time@theguardian.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aker BP's Q3 2026: Strong Earnings Fuel Optimism

Third Quarter Overview: Riding the Wave Aker BP's third quarter report is a raucous symphony of successes that have the market nodding in admiration. Marking significant strides with their offshore projects, the company seems to be in a cavalier mood as it boasts higher sales volumes and promising financials. Net production came in at 374 mboepd, dampened slightly by...

Eric Dalton: Redefining Homecare with Vision and Strategy

What's Behind Eric Dalton's Continued Recognition? Now, if you told me a healthcare leader’s named 'Visionary of the Year' twice in a row, my first thought isn't 'stretch goals' but 'show me the goods.' And that’s precisely what Eric J. Dalton has done. The Vice President at Angels on Call Homecare isn't just tooting his own horn; he's building a damn symphony in the...

Labcorp Lifts 2026 Guidance Amid Strong Q3 Performance

Labcorp's Q3 Numbers Speak Loud and Clear Another quarter, another robust set of numbers for Labcorp (NYSE:LH). The company is strutting into the spotlight with third-quarter 2026 results that have investors nodding in approval. Revenue surged to $3.81 billion, marking a 6.9% increase from the prior year's $3.56 billion. And get this: adjusted EPS jumped 14.5%, clocking...

DERMALOG Bolsters Biometric Defense with Key Wins

DERMALOG Rides High with PAD Success Germany-based DERMALOG just gave biometric crooks a run for their money. In a testament to gutsy tech work, they've hit a homerun with the latest independent security evaluations. They’ve managed to spot and shut down all 1,500 tried and tested spoofs in presentation attacks—think photos, videos, and phony fingerprints. That’s no...

ESENTIA Lifts EBITDA, Reduces Debt, Eyes Expansion

ESENTIA Flexes Financial Muscles: What's the Deal? Walk with me through the gritty world of financials, and you’ll see that ESENTIA’s latest figures are a mixed bag with a tantalizing upside. We're talking about adjusted EBITDA ticking up to a cool $86 million in the third quarter of '26, a 1.3% lift from last year. Not too shabby, eh? Especially when you're grappling...

Quad Sees Marginal Gains Amid Industry Challenges

Treading Water with a Splash of Strategic Moves When you're in the thick of market shifts, sometimes it's not about big leaps but staying afloat with purpose. That's what Quad's recent financial release seems to hint at. A steady net sales figure hovering at $587 million for Q3 2026, barely a nudge compared to last year's numbers, sets the tone. It's not the fireworks...

Arctic Wolf Leads in AI SOC: A 2026 Game Changer

Leading the Pack with AI-Powered Security In the world of cybersecurity, where every day feels like a battlefield, Arctic Wolf has clawed its way to the top spot in the Q4 2026 QKS SPARK Matrix™ for AI SOC Automation. This recognition doesn't just highlight their prowess in handling security operations; it underscores their relentless commitment to infusing AI...

AEP's $100B Power Plan: Investing in Tomorrow's Energy

Electricity Powerhouse Unleashes Ambitious Plan If you thought American Electric Power (NASDAQ:AEP) was just cruising along, think again. This week, they rolled out an eye-popping $100 billion plan to supercharge their infrastructure and meet soaring electricity demands. It’s like they’re building the future of power right in front of our eyes. Third-quarter earnings...

South Dakota's BEES Launch: Child Care Assistance Goes Live

RedMane and South Dakota DSS: A New Milestone Talk about a leap into the digital age. South Dakota's Department of Social Services, teaming up with RedMane Technology, has just rolled out the Child Care Assistance Program on their BEES platform. That’s Benefits Eligibility and Enrollment System for those not keeping track. It represents a significant step in making life...

CapCut Leads 2026 AI Image Tools for Creatives

CapCut Emerges as a Go-To in AI Imagery There's no better feeling than striking gold in a flooded market. CapCut's got folks buzzing in 2026 for its top-tier AI image creation tools, according to Expert Consumers' latest rankings. On the surface, it might just seem like another tech gimmick, but dig a bit deeper, and you'll see why it's a game changer. From adland to...